The article discusses key principles related to adding pathology components to epidemiologic studies, using examples from breast cancer research. An overview of steps involved in developing the pathology components in epidemiologic studies is presented. It also describes the internal and external validity and quality assurance. Additionally, it claims that technical improvements are expected to meet growing demands for use of molecular assays in clinical medicine.